LIVE TV
ZEE Business
ZEE BUSINESS
हिंदी में पढ़ें  हिंदी में पढ़ें
Live TV
Live TV
  • Home
  • Personal Finance
    • PPF
    • Mutual Funds
    • Income tax
    • EPFO
    • Income Tax Calculator
    • Personal Loan Calculator
    • Car Loan Calculator
    • Home Loan Calculator
    • SIP calculator
    • SWP Calculator
    • MF Returns Calculator
    • Lumpsum Calculator
  • India
    • Companies
    • Property
    • Startups
    • Uidai
  • Economy
    • Aviation
  • Tech
    • Mobiles
    • Apps
  • Auto
    • Cars
    • Bikes
  • Markets
    • Commodities
    • Currency
  • Jobs
  • Indian Railways
  • World
    • Economy
    • Politics
    • Markets
  • videos
  • photos
  • Authors
  • More ...
    • VIDEOS
    • PHOTOS
Read in App
Business News » Markets News

Aurobindo Pharma Share price: Sharekhan retains their Buy recommendation with a revised Price target of Rs 1100

Aurobindo Pharma Q3 FY21 revenue, operating profits and PAT were a tad below the estimates. Sales at Rs 6365 cr is up 8% yoy (slightly below estimates), attributable to an 11.3% yoy growth in the formulations segment, while API sales were down 13.6% yoy. OPM expanded by 100 BPS yoy to 21.5% (estimated OPM 22%) led by a 310 bps expansion in gross margins, which were partly offset by an increase in other expenses.

  • Twitter
  • Facebook
  • Linkedin
  • whatapp
  • View in App
Aurobindo Pharma Share price: Sharekhan retains their Buy recommendation with a revised Price target of Rs 1100
Aurobindo Pharma operating profits for the quarter at Rs 1368 cr is up by 13.3% yoy. Adjusting for one-off gains, PAT stood at Rs 836 cr, up 18.5% yoy but missed estimates: Reuters
Reported By: ZeeBiz WebTeam
Written By: Rahul Kamdar
Edited By: Harish Dugh
Updated: Fri, Feb 12, 2021
12:08 pm
Mumbai, ZeeBiz WebDesk
RELATED NEWS
JPMorgan on Aurobindo Pharma stock re-rating trigger and target price JPMorgan on Aurobindo Pharma stock re-rating trigger and target price
Stock Of The Day: Anil Singhvi reveals his top recommendation for investors today - Aurobindo Pharma Stock Of The Day: Anil Singhvi reveals his top recommendation for investors today - Aurobindo Pharma
Aurobindo Pharma share price: Sharekhan retains Buy recommendation with price target of Rs 1100 Aurobindo Pharma share price: Sharekhan retains Buy recommendation with price target of Rs 1100
Aurobindo Pharma, Biocon, Dr Reddy’s Lab and Divi’s Laboratories: Resilient demand points to another good year for Pharma Sector says HSBC Aurobindo Pharma, Biocon, Dr Reddy’s Lab and Divi’s Laboratories: Resilient demand points to another good year for Pharma Sector says HSBC
Nifty to Sensex - All you need to know about markets today Nifty to Sensex - All you need to know about markets today

Aurobindo Pharma Q3 FY21 revenue, operating profits and PAT were a tad below the estimates. Sales at Rs 6365 cr is up 8% yoy (slightly below estimates), attributable to an 11.3% yoy growth in the formulations segment, while API sales were down 13.6% yoy. OPM expanded by 100 BPS yoy to 21.5% (estimated OPM 22%) led by a 310 bps expansion in gross margins, which were partly offset by an increase in other expenses. Sharekhan retains their Buy recommendation on Aurobindo Pharma with a revised Price target of Rs 1100.

Aurobindo Pharma operating profits for the quarter at Rs 1368 cr is up by 13.3% yoy. Adjusting for one-off gains, PAT stood at Rs 836 cr, up 18.5% yoy but missed estimates. Aurobindo’s injectables business is fast gaining traction with increasing number of regulatory approvals and geographic expansion.

See Zee Business Live TV Streaming Below:

Aurobindo Pharma is also in the midst of commissioning an injectables facility in the US and is also setting up a dedicated facility at Vizag for Europe and RoW markets. Based on this, the annual run-rate of the injectables business is expected to reach $ 650-700 million over the next three years versus $ 380 million now. The US formulations business is also on a strong growth footing, backed by a sturdy product pipeline (50 products to be launched in the US each in FY21 and FY22) and growth in base business.

Aurobindo Pharma’s European business also revived, staging a double-digit revenue growth. Driven by the transition in favor of TLD, the anti-retro-viral (ARV) segment’s revenues are expected to grow strongly. Further, Aurobindo is investing Rs 1500 cr ($200-220 million) annually towards capacity expansion over FY21 and FY22, which offers ample growth visibility. In the long term, vaccines and APIs are expected to be the growth drivers.

Aurobindo Pharma is looking to double its API sales over the next 4 years, largely driven by the capex under the PLI scheme, though it is at planning stage. It would be developing PCV (Pneumococcal Conjugate Vaccine) and has also entered into agreement with a US company to manufacture viral vaccines. Also it is doubling its vaccine capacity to 440 million doses from 220 million doses by June 2021. Successful clearance from USFDA for five plants is awaited as the company has submitted its responses. In the long term, focus on building and developing a strong portfolio of specialty products (biosimilars, oncology, inhalers, transdermal patches, etc) would be key growth drivers.

Aurobindo Pharma Key positives:

European sales grew 13.2% yoy, better than estimates
ARV business grew sturdily by 41.5% yoy due to transition to combination drug TLD
OPM expanded by 100 bps y-o-y to 21.5% backed by a 310 bps expansion in gross margins
Aurobindo Pharma turned cash positive with net cash of Rs 117 cr as of December 2020

Aurobindo Pharma Key negatives:

API segment revenues declined by 13.6% yoy due to a 24.3% decline in Betalactum sales
USFDA clearance for five plants (unit I, IX, XI, VII and US) is yet to be received

Aurobindo Pharma Key Risks:

Delay in resolution of USFDA issues and product approvals; change in regulatory landscape; and negative outcome of key facility inspection by USFDA can affect earnings prospects.

 

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

TAGS:
Aurobindo PharmaAurobindo
RELATED NEWS
JPMorgan on Aurobindo Pharma stock re-rating trigger and target price JPMorgan on Aurobindo Pharma stock re-rating trigger and target price
Stock Of The Day: Anil Singhvi reveals his top recommendation for investors today - Aurobindo Pharma Stock Of The Day: Anil Singhvi reveals his top recommendation for investors today - Aurobindo Pharma
Aurobindo Pharma share price: Sharekhan retains Buy recommendation with price target of Rs 1100 Aurobindo Pharma share price: Sharekhan retains Buy recommendation with price target of Rs 1100
Aurobindo Pharma, Biocon, Dr Reddy’s Lab and Divi’s Laboratories: Resilient demand points to another good year for Pharma Sector says HSBC Aurobindo Pharma, Biocon, Dr Reddy’s Lab and Divi’s Laboratories: Resilient demand points to another good year for Pharma Sector says HSBC
Nifty to Sensex - All you need to know about markets today Nifty to Sensex - All you need to know about markets today

LATEST NEWS

WhatsApp, Facebook suffer big setback in India! Know how they have been affected

Anil Singhvi decodes fall in US markets on Thursday, reveals strategy for investors

Google searches for oxygen cylinder, Remdesivir skyrocket in India! Check all details here

Covid-19 registration for 18 plus begins on THIS date; check how you can register on cowin.gov.in

Amarnath Yatra registration suspended; window to register for 56 day-yatra to reopen after assessing Covid-19 situation on later date

COVID-19: Hospitals in Delhi-NCR short on oxygen, send SOS to Govt - All details here

Maharashtra hospital fire: 13 die in Virar ICU blaze

CBSE students' alert: BIG change! Board releases new assessment and evaluation practices—check details here

Shravan Rathod of Nadeem-Shravan fame DIES due to Covid 19-related complications

WhatsApp Pink - a new virus now threatens users accounts; find out what it is and how to stay safe

  • India News
  • World News
  • Companies News
  • Market News
  • Personal Finance News
  • Technology News
  • Automobile News
  • Small Business News
  • Income Tax Calculator
  • Live TV
  • Videos
  • Photos
  • Author
  • Rss Feed
  • Advertise with us
  • Privacy Policy
  • Legal Disclaimer

Latest Trending Updates

  • EPFO
  • Budget 2020
  • Income Tax Return
  • Auto Expo 2020
  • Home Loan
  • Business News

Trending Topics

  • Income Tax
  • income Tax Calculator
  • 7th Pay Commission
  • Reserve Bank of India
  • GST
  • Latest Business News

Follow us on

zeebiz
zeebiz

Partner Sites

  • Zee News
  • Hindi News
  • Marathi News
  • Bengali News
  • Tamil News
  • Malayalam News
  • Gujarati News
  • Telugu News
  • Kannada News
  • DNA
  • WION
Copyright © Zee Media Corporation Ltd. All rights reserved